Clinics in Dermatology
Volume 27, Issue 6, Supplement , Pages S48-S53 , November 2009

An investigator-blind, randomized, 4-week, parallel-group, multicenter pilot study to compare the safety and efficacy of a nonsteroidal cream (Promiseb Topical Cream) and desonide cream 0.05% in the twice-daily treatment of mild to moderate seborrheic dermatitis of the face

References 

  1. Bikowski J. Facial seborrheic dermatitis: a report on current status and therapeutic horizons. J Drugs Dermatol. 2009;8:125–133
  2. DeAngelis YM, Gemmer CM, Kaczvinsky JR, Kenneally DC, Schwartz JR, Dawson TL. Three etiologic facets of dandruff and seborrheic dermatitis: Malassezia fungi, sebaceous lipids, and individual sensitivity. J Investig Dermatol Symp Proc. 2005;10:295–297
  3. Mayo Clinic Web site . Seborrheic dermatitis. Available at: http://www.mayoclinic.com/health/seborrheicdermatitis/DS00984Accessed: May 14, 2009
  4. Barnes PJ. Anti-inflammatory actions of glucocorticoids: molecular mechanisms. Clin Sci (Lond). 1998;94:557–572
  5. Naldi L, Rebora A. Clinical practice. Seborrheic dermatitis. N Engl J Med. 2009;360:387–396
  6. McGinley KJ, Leyden JJ, Marples RR, Kligman AM. Quantitative microbiology of the scalp in non-dandruff, dandruff, and seborrheic dermatitis. J Invest Dermatol. 1975;64:401–405
  7. Bergbrant IM. Seborrheic dermatitis and Pityrosporum ovale: cultural, immunological and clinical studies. Acta Derm Venereol Suppl (Stockh). 1991;167:1–36
  8. Dawson TL. Malassezia globosa and restricta: breakthrough understanding of the etiology and treatment of dandruff and seborrheic dermatitis through whole-genome analysis. J Investig Dermatol Symp Proc. 2007;12:15–19
  9. Gupta AK, Bluhm R, Barlow JO, Fleischer AB, Feldman SR. Prescribing practices for seborrheic dermatitis vary with the physician's specialty: implications for clinical practice. J Dermatolog Treat. 2004;15:208–213
  10. Kircik L. An open-label, single-center pilot study to determine the antifungal activity of a new nonsteroidal cream (Promiseb Topical Cream) after 7 days of use in normal volunteers. Clin Dermatol. 2009;27(Suppl 2):S44–S47
  11. Nalamothu V, O'Leary AL, Kandavalli S, Fraser J, Pandya V. Evaluation of a nonsteroidal topical cream in a guinea pig model of Malassezia furfur infection. Clin Dermatol. 2009;27(Suppl 2):S41–S43
  12. Veraldi S, Menter A, Innocenti M. Treatment of mild to moderate seborrhoeic dermatitis with MAS064D (Sebclair), a novel topical medical device: results of a pilot, randomized, double-blind, controlled trial. J Eur Acad Dermatol Venereol. 2008;22:290–296
  13. Promiseb [package insert]. Bridgewater (NJ): Promius Pharma, LLC; 2009;
  14. Koo J, Lebwohl M. Duration of remission of psoriasis therapies. J Am Acad Dermatol. 1999;41:51–59

☆ Dr Elewski has received clinical grant funding from and is a consultant to Johnson & Johnson and Stiefel Laboratories, Inc. The clinical trial number for this study is PSC0801.

PII: S0738-081X(09)00192-8

doi: 10.1016/j.clindermatol.2009.09.002

Clinics in Dermatology
Volume 27, Issue 6, Supplement , Pages S48-S53 , November 2009

Article Tools

* Image Usage & Resolution